Schisandrin C

SKU: orb1221962

Description

Schizandrin C is a compound that exerts anti-neuroinflammatory effects by upregulating phase II detoxifying/antioxidant enzymes in microglia.(In Vitro):Schisandrin C (25-100 μM; 48 hours) down-regulates expression levels of Bcl-2, Bcl-xL and a concomitant degradation of poly(ADP-ribose) polymerase (PARP). It also activates caspase-3 and -9 in U937 cells.Schisandrin C (25-100 μM; 48 hours) induces apoptosis in a dose-dependent manner. And the fragmentation of genomic DNA is also increased in U937 cells.Schisandrin C (25-100 μM; 72 hours) induces G1 arrest, it down-regulates cyclin D1, cyclin E, cyclin-dependent kinase (Cdk) 4 and E2Fs expression, and also exhibits inhibition of pRB, and up-regulation of the Cdk inhibitor p21(WAF1/CIP1).(In Vivo):Schisandrin C (lateral ventricle injection (i.c.v.); 15-150 μg/kg; 5 days) reduces Aβ1-42-induced memory deficits in the Y-maze test. Neurons in the hippocampus of SCH-C (15 μg/kg)-treated group returned to normal level, and and SCH-C group (150 μg/kg) has slight neuroprotective effects Aβ1-42-induced group. SCH-C (15 μg/kg) recoveres the activities of SOD and GSHPx and the ratios of GSH, decreases the levels of ChEtotal in the brain of the Aβ1–42-induced amnesic mice simultaneously.

Key Properties

• CAS Number: 61301-33-5
• MW: 384.42
• Purity: >98% (HPLC)
• Formula: C₂₂H₂₄O₆
• SMILES: C[C@H]1Cc4cc5OCOc5c(OC)c4c2c(OC)c3OCOc3cc2C[C@H]1C
• Target: Others
• Solubility: In Vitro: DMSO : 8.33 mg/mL (21.67 mM)

Bioactivity

• In Vivo:
  Schisandrin C (lateral ventricle injection (i. c. v.); 15-150 μg/kg; 5 days) reducesAβ1-42-induced memory deficits in the Y-maze test. Neurons in the hippocampus of SCH-C (15 μg/kg)-treated group returned to normal level, and and SCH-C group (150 μg/kg) has slight neuroprotective effects Aβ1-42-induced group. SCH-C (15 μg/kg) recoveres the activities of SOD and GSHPx and the ratios of GSH, decreases the levels of ChEtotal in the brain of the Aβ1–42-induced amnesic mice simultaneously. Animal model: Aβ1-42-induced Alzheimer’s disease mice. Dosage: 15-150 μg/kg. Administration: Lateral ventricle injection (i. c. v.); 15-150 μg/kg; 5 days. Result: Exhibited potent neuroprotective effects linking to anti-ChEtotal activities and anti-oxidative mechanisms in Aβ1-42-induced amnestic mice.
• In Vitro:
  Schisandrin C (25-100 μM; 48 hours) down-regulates expression levels of Bcl-2, Bcl-xL and a concomitant degradation of poly(ADP-ribose) polymerase (PARP). It also activates caspase-3 and -9 in U937 cells. Schisandrin C (25-100 μM; 48 hours) induces apoptosis in a dose-dependent manner. And the fragmentation of genomic DNA is also increased in U937 cells. Schisandrin C (25-100 μM; 72 hours) induces G1 arrest, it down-regulates cyclin D1, cyclin E, cyclin-dependent kinase (Cdk) 4 and E2Fs expression, and also exhibitsinhibition of pRB, and up-regulation of the Cdk inhibitor p21(WAF1/CIP1). Western blot analysis. Cell line: U937 cells. Concentration: 25 μM, 50 μM, 100 μM. Incubation time: 48 hours. Result: Decreased the expression of apoptosis related proteins. Apoptosis Analysis Cell line: U937 cells. Concentration: 25 μM, 50 μM, 100 μM. Incubation time: 48 hours. Result: Induced cell apoptosis. Cell Cycle Analysis Cell line: U937 cells. Concentration: 25 μM, 50 μM, 100 μM. Incubation time: 48 hours. Result: Induced growth inhibition and G1 arrest of U937 cells.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Schizandrin C | Schizandrin-C

Quick Database Links

Gene Symbol

Others